Acadian Asset Management LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 2nd quarter, Holdings Channel reports. The firm bought 593 shares of the biopharmaceutical company’s stock, valued at approximately $112,000.
Several other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock worth $1,768,291,000 after purchasing an additional 126,373 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.7% in the 1st quarter. BlackRock Inc. now owns 8,548,962 shares of the biopharmaceutical company’s stock worth $1,712,528,000 after buying an additional 59,582 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock valued at $761,144,000 after purchasing an additional 10,609 shares during the period. State Street Corp increased its position in shares of Alnylam Pharmaceuticals by 2.1% during the 1st quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock valued at $475,091,000 after purchasing an additional 59,101 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 2.9% in the 1st quarter. Geode Capital Management LLC now owns 1,738,115 shares of the biopharmaceutical company’s stock worth $347,684,000 after purchasing an additional 48,186 shares during the period. 93.98% of the stock is owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Stock Performance
Shares of NASDAQ ALNY opened at $165.26 on Tuesday. The firm’s fifty day moving average is $170.13 and its two-hundred day moving average is $185.94. Alnylam Pharmaceuticals, Inc. has a 52-week low of $148.10 and a 52-week high of $242.97. The company has a market cap of $20.74 billion, a P/E ratio of -39.92 and a beta of 0.47.
Wall Street Analyst Weigh In
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- What is Forex and How Does it Work?
- The most upgraded stocks in November have two things in common
- Crypto vs Stocks: How to Choose Your Investments
- Monday.com rocked earnings like it’s the weekend
- How to Invest in Cybersecurity
- Plan to own one retailer? Make it this one
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.